|
|
Build Your Online Product Catalogs?
| Product Name: |
Small Molecular Erlotinib Hydrochloride (CAS No.:
|
| Supply Ability: |
100g |
| Related proudcts |
api, pharmaceutical, intermediate, |
| Specifications |
medicine grade |
| Price Term: |
FOB,CNF,CIF |
| Port of loading: |
Shenzhen |
| Minimum Order |
100 |
| Unit Price: |
2.5 |
|
Small Molecular Erlotinib Hydrochloride
(CAS No.: 183319-69-9)
Chemical Information
Product Name Erlotinib hydrochloride
Molecular Formula C22H24ClN3O4
Molecular Weight 429.91
Storage Store at -20°C
Targets HER1 EGFR
IC50 2 nM 2 nM
Erlotinib hydrochloride
CAS 183319-69-9
CAS 183319-69-9 Brand: NEWBIO
MF C22H24ClN3O4 EINECS:ND
MW 429.9 MOQ: 100grams
Product Categories: API;Molecular Targeted Antineoplastic;Heterocyclic Compounds;anti-neoplastic;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Usage Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche.
Applications Erlotinib hydrochloride , Pharmaceutical raw materials
Description
Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells.
Application
Cells were treated with single dose of erlotinib (1 µM, 24 hours), The greatest cell death was observed in the Txt->OSI-774->media sequence, while the cells treated with the OSI-774->Txt->media sequence resumed proliferation by 72hrs post-treatment. Cleaved PARP and Ca***se-3 were ***ected in the sequence of Txt->OSI-774, and with simultaneous treatment, but not in the sequence of OSI-774->Txt. Further, cleaved PARP and Ca***se-3 persisted to 72hrs after the Txt->OSI-774 treatment. These |
| Company: |
Wuhan Newbio Pharm-tech Co., Ltd.
|
| Contact: |
Mr. Jason Edwards |
| Address: |
858, East Lake, High-Tech Development Zone, Wuhan, Hubei, China |
| Postcode: |
430075 |
| Tel: |
+86-027-87002705 |
| Fax: |
86-27-87050469 |
| E-mail: |
|
|
|
|
Home
